Why Zalicus (ZLCS) Stock Is Surging Today

NEW YORK (TheStreet) -- Zalicus  (ZLCS) surged Thursday after Epirus Switzerland announced clinical data from a Phase 3 study of BOW015, a biosimilar infliximab, in patients with active rheumatoid arthritis.

The study is as an equivalence trial to compare BOW015 to Remicade. BOW015 reached an ACR20 response rate of 89.8%, compared to 86.4% for Remicade, in week 16. This figure met the previously specified statistical endpoint.

Zalicus and Epirus Biopharmaceuticals entered into a definitive merger agreement on April 15. Epirus would merge with a wholly-owned subsidiary of Zalicus in an all-stock transaction under the agreement.

Must Read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was up 32.42% to $1.43 at 11:06 a.m. More than 7.3 million shares changed hands, which easily surpassed the average volume of 589,406.

ZLCS Price Chart

ZLCS Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Your Need to Know - Forward Look

Your Need to Know - Forward Look

How E-Mini S&P 500 Revolutionized Equity, Electronic Trading

How E-Mini S&P 500 Revolutionized Equity, Electronic Trading

Dow Gains, S&P 500 and Nasdaq Slip; Ford Hits 52-Week Low

Dow Gains, S&P 500 and Nasdaq Slip; Ford Hits 52-Week Low

How to Be a Tactical Investor in the Current Market

How to Be a Tactical Investor in the Current Market

State Street Shares Fall as Earnings Fail to Meet Expectations

State Street Shares Fall as Earnings Fail to Meet Expectations